Trial ID: | L0054 |
Source ID: | NCT00338000
|
Associated Drug: |
Epoetin Alfa
|
Title: |
EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
|
Acronym: |
|
Status: |
COMPLETED
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Chronic Renal Failure
|
Interventions: |
DRUG: Epoetin alfa
|
Outcome Measures: |
Primary: Hemoglobin change - reach of target Hb levels (measured at Visit 1, 2, 3, 4) | Secondary: Prevention of left ventricular hypertrophy (measured at Visit 3 and 4)
|
Sponsor/Collaborators: |
Sponsor: Janssen Pharmaceutica N.V., Belgium
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE4
|
Enrollment: |
292
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2001-06
|
Completion Date: |
2005-05
|
Results First Posted: |
|
Last Update Posted: |
2011-02-01
|
Locations: |
|
URL: |
https://clinicaltrials.gov/show/NCT00338000
|